Get the weekly longevity research breakdown → Join free
NMN and NR supplement capsules compared for NAD+ longevity research
Science & ResearchSupplements

NMN vs NR: What Longevity Experts Actually Recommend in 2026

By Mike Hartnett
March 1, 2026 24 Min Read
19 0

Affiliate Disclosure: CoreStacks may earn a commission through affiliate links in this article. This does not affect our editorial independence or how we report on expert recommendations. See our full disclosure.

Table Of Content

The Bottom Line on NMN vs NR in 2026

The NMN vs NR debate has shifted significantly since 2023. The FDA’s exclusion of NMN from the dietary supplement category disrupted the market, while nicotinamide riboside (NR) remains the only NAD+ precursor with FDA GRAS status. Experts are split: David Sinclair and Andrew Huberman still take NMN daily, while Peter Attia and Brad Stanfield argue neither has sufficient human evidence to justify supplementation. The honest answer is that the science remains unsettled — and where each expert lands depends on their threshold for acting on preliminary data.

Quick Comparison: NMN vs NR at a Glance

Before diving into what each expert says, here is how these two NAD+ precursors compare on the factors that matter most.

Factor NMN (Nicotinamide Mononucleotide) NR (Nicotinamide Riboside)
Molecular Weight 334.2 g/mol 255.2 g/mol
Conversion to NAD+ NMN -> NAD+ (one step) NR -> NMN -> NAD+ (two steps)
Oral Bioavailability Debated; recent studies suggest direct transport via Slc12a8 Established; converted to NMN in the liver
FDA Supplement Status Excluded from dietary supplement definition (2022-2023) GRAS status (as Niagen by ChromaDex)
Key Clinical Trials Multiple small trials (n=30-80); larger trials ongoing Several published RCTs (n=40-140); CHROMAVITA series
Primary Brand Multiple (ProHealth, DoNotAge, Renue By Science) ChromaDex (Niagen/Tru Niagen)
Typical Daily Dose 250mg-1,000mg 300mg-1,000mg
Cost per Month (est.) $40-$120 (varies widely by brand) $40-$60 (Tru Niagen standard)
Third-Party Testing Varies by brand; no single standard ChromaDex controls Niagen supply chain
Expert Consensus Sinclair, Huberman take it; Attia, Stanfield reject it Johnson alternates with NMN; most skeptics reject both
Human Evidence Strength Preliminary — multiple small RCTs, mixed results Moderate — more published RCTs, consistent NAD+ elevation
Patent Landscape Complex; Metro International Biotech holds key patents ChromaDex holds key patents on Niagen

Get the latest longevity research in your inbox every week.

Join Free →

The Science: How NAD+ Precursors Work

To understand why this debate exists, you need to understand what NMN and NR are actually doing in the body.

NAD+ and Why It Declines

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell in the body. It is essential for hundreds of metabolic processes, including energy production in the mitochondria, DNA repair via sirtuin and PARP enzymes, circadian rhythm regulation, and immune cell function.

The core problem: NAD+ levels decline with age. Multiple studies have documented that NAD+ levels in human tissues can drop by as much as 50% between the ages of 40 and 60. This decline has been linked in research to age-related metabolic dysfunction, neurodegeneration, and cardiovascular disease — though the causal direction remains a subject of active investigation.

As Dr. Rhonda Patrick explained on FoundMyFitness, “NAD+ sits at the intersection of nearly every major aging pathway. The question is not whether NAD+ decline matters — it clearly does — but whether oral supplementation of precursors can meaningfully restore levels in the tissues where it counts.”

NMN: One Step Away from NAD+

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+. Inside the cell, the enzyme NMNAT converts NMN to NAD+ in a single step. This is the primary argument for NMN over NR: it is one enzymatic step closer to the end product.

In 2019, a team led by Shin-ichiro Imai at Washington University published research in Nature Metabolism identifying a transporter called Slc12a8 that appears to move NMN directly into cells without requiring conversion to NR first. This was a significant finding because it challenged the earlier assumption that NMN must be broken down to NR before crossing cell membranes.

However, this transporter has been the subject of debate. Some researchers have questioned whether Slc12a8 transports NMN at sufficient rates in human tissues to be physiologically relevant. The discussion remains unresolved.

NR: The Two-Step Path

NR (nicotinamide riboside) is converted to NMN by the enzyme NRK (nicotinamide riboside kinase), and then NMN is converted to NAD+ by NMNAT. This two-step pathway is well-established biochemistry, and NR’s ability to raise blood NAD+ levels has been demonstrated consistently in human trials.

The counterargument to NMN’s “one step closer” advantage is practical: NR has been shown to reliably enter cells via equilibrative nucleoside transporters, a well-characterized pathway. ChromaDex, the company behind Niagen (the patented form of NR), has funded multiple human trials confirming that oral NR at 300-1,000mg per day raises whole blood NAD+ levels by 40-90% within two weeks.

The Real Question

The debate is not really about which molecule raises blood NAD+ levels more effectively — both appear to do so. The real question, as Peter Attia has pointed out repeatedly on The Drive podcast, is whether raising blood NAD+ translates to meaningful health outcomes in humans. As of February 2026, neither NMN nor NR has demonstrated a clear clinical endpoint benefit (reduced disease incidence, improved mortality, or measurable healthspan extension) in a large, well-powered randomized controlled trial.

What Each Expert Says

The longevity expert community is genuinely divided on NAD+ precursor supplementation. Here is where each major voice currently stands, based on their most recent public statements.

David Sinclair — NMN Advocate

Position: Takes NMN daily. Has called it a cornerstone of his longevity protocol.

Current dose (publicly stated): 1g NMN per day, taken in the morning with yogurt.

David Sinclair, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, is the single most prominent advocate for NMN supplementation. His 2019 book Lifespan brought NAD+ biology into mainstream conversation, and his lab has published multiple papers on NMN’s effects in animal models.

In a June 2025 interview with Peter Diamandis, Sinclair reiterated that he takes 1g of NMN daily, along with resveratrol and other compounds. He has stated that his biological age, as measured by epigenetic clocks, is significantly younger than his chronological age — though he has acknowledged that attributing this to any single intervention is impossible given his multi-compound protocol.

Sinclair’s lab published results in Science (2017) showing that NMN treatment restored NAD+ levels and reversed vascular aging in old mice, and a study in Cell (2018) demonstrating NMN’s effects on age-related muscle decline in mice. His team’s more recent work has focused on epigenetic reprogramming, but NMN remains part of his publicly discussed personal protocol.

Key caveat: Sinclair has financial interests in NAD+ precursor science. He co-founded Metro International Biotech, which holds patents related to NMN. He has disclosed these interests publicly, but they are relevant context when weighing his advocacy.

Source: Lifespan (2019); Diamandis interview (June 2025); published papers in Science (2017), Cell (2018), Nature Metabolism (2019)

Andrew Huberman — NMN User

Position: Takes NMN. Has also used NR.

Current dose (publicly stated): 1-2g NMN per day (sublingual form). Has also mentioned taking 500mg NR.

Andrew Huberman, professor of neurobiology at Stanford School of Medicine and host of the Huberman Lab podcast, has discussed NAD+ precursors across multiple episodes. On his podcast and in interviews with Tim Ferriss and others, Huberman has shared that he takes NMN sublingually, citing the potential for improved bioavailability when bypassing the gut.

In podcast episodes discussing his supplement stack, Huberman has noted that he takes NMN primarily for its potential effects on cellular energy and repair pathways. He has also mentioned taking NR at 500mg per day, suggesting he does not view them as mutually exclusive.

Huberman has been careful to note that his supplementation is based on his own assessment of the emerging data and his personal health metrics, and that listeners should consult their physicians. He has not published original research on NMN or NR himself — his expertise is in neuroscience and vision, not aging biology — but he frequently interviews researchers who work in this space.

Source: Huberman Lab podcast (multiple episodes on supplementation); Tim Ferriss Show #660; AMA episodes

Peter Attia — Skeptic of Both

Position: Does not take NMN or NR. Has never publicly reported taking either.

Reason: Insufficient human evidence for clinical benefit.

Peter Attia, physician and host of The Drive podcast, represents the most evidence-demanding position in this debate. In multiple podcast episodes and in his 2023 book Outlive: The Science and Art of Longevity, Attia has expressed skepticism about NAD+ precursor supplementation.

Attia’s core argument, articulated across several Drive podcast episodes, centers on a distinction between surrogate endpoints and clinical endpoints. He has acknowledged that both NMN and NR can raise blood NAD+ levels — but he argues that NAD+ level itself is a surrogate marker, and that no published human trial has demonstrated that raising NAD+ via supplementation leads to a measurable health outcome that patients actually care about (reduced disease, improved function, extended life).

In his framework, he places NAD+ precursors in a category of interventions with “interesting mechanistic data, strong animal data, and insufficient human data.” He has compared the situation to resveratrol, which showed promise in animal models for years before the human data largely failed to deliver.

Attia has also raised concerns about the purity and quality control issues in the NMN supplement market, particularly after the FDA’s regulatory action.

Source: The Drive podcast (episodes on NAD+ biology, supplement frameworks); Outlive (2023); AMA episodes on supplementation

Brad Stanfield — Evidence-Based Skeptic

Position: Dropped NMN. Does not take NR. Prefers low-dose niacinamide (plain nicotinamide) if anything.

Reason: Human RCT data does not support the cost or the hype.

Dr. Brad Stanfield, a New Zealand-based physician and YouTuber with over 275,000 subscribers focused on evidence-based longevity, has produced several detailed videos analyzing the NMN and NR literature. His position has evolved over time — he previously took NMN before publicly stopping and explaining his reasoning on his YouTube channel.

Stanfield’s analysis focuses on what the published human randomized controlled trials actually show. In his assessment, the human RCTs for NMN are small (typically n=30-80), short-duration (8-12 weeks), and while they generally show NAD+ elevation, they have not consistently demonstrated functional improvements that justify the cost.

On NR, Stanfield has noted that the evidence base is slightly more robust — more published RCTs, including ChromaDex-funded trials — but he arrives at a similar conclusion: consistent NAD+ elevation without consistent clinical benefit.

Stanfield’s alternative recommendation, discussed in several videos, is low-dose niacinamide (nicotinamide, also called vitamin B3) at around 250-500mg per day. He has cited research suggesting that plain niacinamide can support NAD+ levels at a fraction of the cost of NMN or NR, and has referenced a 2023 study published in Nature Aging examining niacinamide’s effects on NAD+ metabolism.

Source: YouTube channel (multiple videos on NMN, NR, and niacinamide); drstanfield.com supplement page

Rhonda Patrick — Nuanced NAD+ Biologist

Position: Has discussed NAD+ biology extensively. Has taken NR. Views both as potentially beneficial but acknowledges evidence gaps.

Dr. Rhonda Patrick, biomedical scientist and founder of FoundMyFitness, has produced some of the most detailed explanations of NAD+ biology available to a general audience. Her approach is more nuanced than either the advocacy or skeptic camps.

Patrick has discussed the biochemistry of both pathways in depth on her podcast and in her research summaries. She has taken NR (specifically Tru Niagen) and discussed it on her podcast, noting the published human data showing reliable NAD+ elevation. She has also covered NMN research, including the Slc12a8 transporter discovery and the ongoing debate about oral bioavailability.

Her position, as articulated across multiple FoundMyFitness episodes, can be summarized as: the biology of NAD+ decline is real and important; both NMN and NR can raise NAD+ levels; but the evidence for specific clinical benefits in humans remains preliminary. She has emphasized the importance of ongoing clinical trials that may clarify the picture in the next two to three years.

Source: FoundMyFitness podcast (NAD+ episodes); foundmyfitness.com research summaries; social media posts on NAD+ biology

My Experience With NMN

I’ll be straight with you — I take NMN capsules daily and I can’t tell you I feel dramatically different because of it. The effect is subtle. I’m not bouncing off the walls with energy, I’m not suddenly aging in reverse. If someone told me tomorrow that NMN was no better than placebo, I wouldn’t be shocked.

So why do I keep taking it? Because the research on NAD+ decline with aging is compelling enough that I’m willing to bet $30-40 a month on it being right. The Sinclair lab data, the more recent human trials showing NAD+ level increases — there’s enough there that I’d rather take it and not need it than skip it and wish I hadn’t.

I chose NMN over NR because of the bioavailability data and because Sinclair and Huberman both prefer it. That said, I think the NMN vs NR debate is one of those things the internet fights about way more than the actual science warrants. Both raise NAD+ levels. Both have decent safety profiles. Pick one, stay consistent, and move on to things that matter more — like whether you’re actually exercising and sleeping enough.

The one thing I will say is don’t cheap out on NMN. Quality varies wildly between brands, and if you’re taking a poorly manufactured product, you’re basically just donating money to a supplement company. Third-party testing matters here more than almost any other supplement.

I break down what the research actually says about longevity compounds — no hype, no guru worship. The CoreStacks Longevity Report is free and lands weekly.

Get the latest longevity research in your inbox every week.

Join Free →

The Research: Published Clinical Trials

The gap between animal research and human evidence is the central issue in this debate. Here is what the published human trials actually show as of February 2026.

NMN Human Trials

Yi et al. (2023) — New England Journal of Medicine correspondence:

A 12-week randomized, double-blind, placebo-controlled trial of 80 middle-aged adults taking 600mg or 1,200mg NMN daily. Results showed significant increases in blood NAD+ levels. The higher dose group showed improvements in physical performance metrics (six-minute walk test), though the improvements were modest. This is one of the more rigorous NMN trials published to date.

Yoshino et al. (2021) — Science:

Led by Shin-ichiro Imai’s group at Washington University. A 10-week study of 25 postmenopausal women with prediabetes taking 250mg NMN daily. Results showed improved insulin sensitivity in skeletal muscle but no significant changes in body composition, blood pressure, or lipids. The sample size was small, but the insulin sensitivity finding was notable.

Igarashi et al. (2022) — NPJ Aging:

A 12-week trial in 30 healthy middle-aged adults taking 250mg NMN. Showed increased NAD+ and improvements in some markers of physical performance. Small sample size limits generalizability.

Katayoshi et al. (2023):

A 12-week RCT showing NMN supplementation improved sleep quality metrics in older adults. The study was small but added sleep to the list of potential NMN-responsive endpoints.

NR Human Trials

Martens et al. (2018) — Nature Communications:

A 6-week crossover trial in 24 healthy older adults taking 500mg NR (Niagen) twice daily. Showed NAD+ elevation of approximately 60% and a trend toward reduced aortic stiffness and reduced systolic blood pressure, though the blood pressure finding did not reach statistical significance. This trial has been frequently cited by both NR advocates and skeptics — advocates point to the blood pressure trend, skeptics point to its non-significance.

Elhassan et al. (2019) — Cell Reports:

A study in 12 older adults showing NR raised NAD+ levels in skeletal muscle and induced changes in the muscle transcriptome consistent with reduced inflammation. Small study but notable for demonstrating tissue-level NAD+ changes, not just blood levels.

Dollerup et al. (2018, 2019, 2020) — Multiple publications:

A series of trials by the Treebak group in Denmark studying NR in obese, insulin-resistant men. Found that NR raised NAD+ but did not improve insulin sensitivity, mitochondrial function, or body composition. These null results are important counterbalance to the positive NMN findings on insulin sensitivity.

Conze et al. (2019) — Scientific Reports:

ChromaDex-funded safety study showing NR at doses up to 1,000mg twice daily was well tolerated with no serious adverse events over 8 weeks.

The Meta-Picture

If you read across all published human RCTs for both NMN and NR as of February 2026, the consistent finding is:

  1. Both reliably raise blood NAD+ levels. This is well-established and not seriously debated.
  2. Clinical benefits are inconsistent. Some trials show improvements in specific endpoints (insulin sensitivity, physical performance, sleep quality); others show no functional improvement despite NAD+ elevation.
  3. No trial has demonstrated a “hard” clinical endpoint — reduced disease incidence, mortality benefit, or measurable healthspan extension.
  4. Sample sizes remain small. Most trials have 25-80 participants. Larger trials are underway but results have not yet been published.

This is the data landscape that explains why experts disagree. They are looking at the same studies and reaching different conclusions based on their individual thresholds for evidence.

The FDA Factor: Why NMN’s Regulatory Status Matters

One of the most significant developments in the NMN vs NR debate has nothing to do with biology — it is regulatory.

NMN’s Exclusion from the Supplement Category

In late 2022, the FDA issued a determination that NMN cannot be marketed as a dietary supplement in the United States. The reasoning: NMN was being investigated as a new drug (by Metro International Biotech, co-founded by David Sinclair) before it was marketed as a supplement, which under the Federal Food, Drug, and Cosmetic Act excludes it from the supplement definition.

This determination was challenged by the Natural Products Association and NMN supplement manufacturers. As of February 2026, the legal and regulatory situation remains in flux. Some NMN products continue to be sold in the U.S. through various legal arguments, while others have shifted to selling NMN as a “research chemical” or through international channels.

The practical impact for consumers:

  • Quality control concerns: Without clear FDA supplement oversight, NMN products vary significantly in purity and potency. Third-party testing becomes critical.
  • Market fragmentation: Some reputable brands have maintained high manufacturing standards (ProHealth Longevity, DoNotAge, Renue By Science), but the market also includes products with questionable testing.
  • Price volatility: Regulatory uncertainty has affected pricing. Some NMN products have become cheaper as manufacturers compete, while others have increased prices to reflect higher testing costs.

NR’s GRAS Status

NR, specifically as ChromaDex’s Niagen, has FDA GRAS (Generally Recognized As Safe) status. This means:

  • It is legally sold as a dietary supplement in the U.S.
  • ChromaDex controls the supply chain for Niagen, which provides more consistent quality.
  • The regulatory pathway is established and stable.
  • Safety data has been submitted to and reviewed by the FDA.

This regulatory asymmetry is a meaningful practical difference. Whatever the scientific debate, NR currently exists in a clearer legal and quality-control framework in the United States.

Price and Availability Comparison

Cost per effective dose is a practical consideration that many expert discussions overlook. Here is how the two compare as of February 2026.

NMN Pricing

Brand Product Dose/Serving Monthly Cost (at 1g/day) Third-Party Tested
ProHealth Longevity NMN Pro 500 500mg/capsule ~$80-100 Yes (BSCG, NSF)
DoNotAge Pure NMN 500mg/capsule ~$60-80 Yes (independent lab)
Renue By Science LIPO NMN 250mg/capsule (liposomal) ~$80-110 Yes (COA available)
Generic/Amazon brands Various 250-500mg ~$30-60 Often unclear

Check current pricing on Amazon

Check current pricing on Amazon

Check current pricing on Amazon

Important note on NMN quality: Given the regulatory uncertainty, third-party testing is especially important for NMN products. Look for brands that publish Certificates of Analysis (COAs) and use independent testing labs. Brad Stanfield has specifically flagged NMN purity as a concern on his YouTube channel, noting that some tested products have contained significantly less NMN than claimed on the label.

NR Pricing

Brand Product Dose/Serving Monthly Cost (at 600mg/day) Third-Party Tested
Tru Niagen (ChromaDex) Tru Niagen 300mg 300mg/capsule ~$40-50 Yes (ChromaDex controls manufacturing)
Tru Niagen (ChromaDex) Tru Niagen Pro 500mg 500mg/capsule ~$55-70 Yes
Thorne ResveraCel (NR + resveratrol) 300mg NR/capsule ~$50-60 (for NR component) Yes (NSF certified)

Check current pricing on Amazon

Check current pricing on Amazon

Check current pricing on Amazon

Cost Comparison Summary

At commonly discussed doses — 1g NMN vs 600mg NR — the monthly cost is roughly comparable ($50-100/month range), with NR generally being slightly less expensive and more consistent in pricing due to ChromaDex’s controlled supply chain.

However, Brad Stanfield’s budget alternative is worth noting: plain niacinamide (nicotinamide) at 250-500mg per day costs approximately $5-10 per month. If your primary goal is supporting NAD+ levels and you are not convinced by the additional benefits of NMN or NR specifically, this represents a dramatically cheaper option.

What’s Changed Recently (2024-2026 Updates)

The NMN vs NR landscape has shifted in several important ways over the past two years.

Regulatory Developments

  • The FDA’s NMN exclusion determination continues to be challenged. Industry groups have filed citizen petitions and the NPA has pursued legal avenues, but as of February 2026, NMN’s status remains in regulatory limbo.
  • Several state-level initiatives have sought to protect NMN supplement sales, creating a patchwork regulatory environment.
  • ChromaDex has used NR’s regulatory clarity as a marketing advantage, positioning Tru Niagen as the “legally established” NAD+ precursor option.

New Research

  • Larger NMN trials have been initiated, including multi-center studies that should provide more robust data. Results from several of these are expected in 2026-2027.
  • The NR research base continues to grow, with new ChromaDex-funded studies examining cardiovascular and cognitive endpoints.
  • A growing body of research has explored combination approaches (NMN + pterostilbene, NR + CoQ10), though results remain preliminary.
  • Research on the Slc12a8 NMN transporter has continued, with additional studies examining its tissue distribution and functional capacity.

Expert Position Updates

  • David Sinclair has maintained his NMN protocol as publicly discussed in his June 2025 Diamandis interview. He has continued to advocate for NAD+ precursor supplementation while acknowledging the need for larger human trials.
  • Brad Stanfield has increasingly promoted low-dose niacinamide as a cost-effective alternative to both NMN and NR, producing several videos comparing the three approaches.
  • Bryan Johnson’s Blueprint protocol, as of recent updates, includes both NMN (500mg, 6 days per week) and NR (300-450mg, alternating), reflecting a pragmatic “hedge both bets” approach.
  • Peter Attia’s position has remained consistent: neither NMN nor NR has met his evidence threshold.

Market Changes

  • NMN prices have generally decreased as competition has increased, despite the regulatory challenges.
  • Sublingual and liposomal NMN formulations have gained market share, driven by claims of improved bioavailability (though human data supporting these specific delivery methods over standard oral capsules is limited).
  • ChromaDex launched Tru Niagen Pro at higher doses, responding to consumer demand for NR products matching the doses used in clinical trials.

Cross-Comparison: Where Experts Agree and Disagree

One of the most useful exercises is mapping where these experts actually overlap — because that is where the signal tends to be strongest.

Points of Agreement

Despite their different positions on NMN and NR, most longevity experts agree on several foundational points:

  1. NAD+ decline with aging is real and relevant. No serious expert disputes that NAD+ levels fall with age or that this decline is associated with metabolic dysfunction. The disagreement is about what to do about it.
  2. The animal data for NAD+ precursors is strong. Multiple well-designed mouse studies have shown that both NMN and NR restore NAD+ levels, improve mitochondrial function, and extend healthspan metrics in aged animals. The disagreement is about whether this translates to humans.
  3. Neither NMN nor NR has proven harmful at standard doses. Safety data from both NMN and NR human trials has been generally reassuring. Neither molecule has shown serious adverse effects at doses up to 1-2g per day over 8-12 week study periods.
  4. Exercise is more important than any NAD+ supplement. Every expert on this list, including Sinclair, has stated that exercise is the single most impactful intervention for longevity. The debate is whether NAD+ precursors add value on top of exercise and other lifestyle foundations.

Points of Disagreement

Question Advocates (Sinclair, Huberman) Skeptics (Attia, Stanfield)
Is animal data sufficient to act? Yes — the risk is low and the biology is compelling No — many promising animal interventions have failed in humans
Is NAD+ elevation a meaningful endpoint? Yes — it indicates restored cellular function No — it is a surrogate marker without proven clinical benefit
Is the cost justified? Yes — for potential prevention of age-related decline No — until human clinical benefit is demonstrated
Which precursor is better? NMN (one step closer, emerging transport data) Neither; if forced to choose, NR (better regulatory status, more human data)
What about plain niacinamide? Less studied for longevity specifically A viable, cheaper alternative (Stanfield’s position)

Related CoreStacks Content:

– The 2026 Longevity Stack: What Huberman, Attia, Sinclair, Johnson & Stanfield Actually Take — Full comparison of every supplement each expert takes

– David Sinclair’s Longevity Protocol (2026 Update) — Complete breakdown of Sinclair’s stack including NMN dosing

– Andrew Huberman’s Supplement Stack (2026 Update) — Everything Huberman currently takes

– Peter Attia’s Supplement Framework — Attia’s evidence hierarchy for supplementation

– Brad Stanfield’s Evidence-Based Stack — Why Stanfield dropped NMN and what he takes instead

– Best NAD+ Supplements in 2026 — Buyer’s guide with third-party testing data

Research Disclaimer

The information in this article is compiled from publicly available expert statements, published peer-reviewed research, and named sources. CoreStacks reports on what experts and researchers say — we do not make independent health recommendations.

Neither NMN nor NR has been approved by the FDA to diagnose, treat, cure, or prevent any disease. The clinical evidence for both remains preliminary, with small sample sizes and short study durations characterizing most published human trials.

Individual responses to supplementation vary. What works for one person — including the experts cited in this article — may not produce the same results for you. Before starting any new supplement, consult a licensed healthcare provider who is familiar with your individual health history, current medications, and health goals.

For our complete medical disclaimer, see CoreStacks Medical Disclaimer.

Frequently Asked Questions

Is NMN or NR better for raising NAD+ levels?

Both NMN and NR have been shown in published human trials to raise blood NAD+ levels significantly. Head-to-head comparison data in humans is limited, so definitive claims about which is “better” at raising NAD+ are not supported by current evidence. David Sinclair has argued that NMN’s single-step conversion to NAD+ gives it a theoretical advantage. ChromaDex-funded research has shown NR reliably raises NAD+ by 40-90% at standard doses. The honest answer is that both work for NAD+ elevation; the question of which is more efficient in human tissues remains under investigation.

Why did the FDA exclude NMN from being sold as a supplement?

The FDA determined in 2022-2023 that NMN was being investigated as a new drug (by Metro International Biotech) before it was marketed as a dietary supplement. Under the Federal Food, Drug, and Cosmetic Act, a substance that has been authorized for investigation as a new drug cannot subsequently be marketed as a supplement unless it was previously marketed as a supplement. This is a legal and regulatory determination, not a safety finding — the FDA did not declare NMN unsafe. The decision has been challenged by industry groups and its long-term resolution remains pending as of February 2026.

Can I take both NMN and NR at the same time?

Some people do. Bryan Johnson’s Blueprint protocol, for example, includes both NMN and NR on alternating schedules. Andrew Huberman has also mentioned taking both. There is no published evidence suggesting that combining them is harmful, but there is also no evidence that combining them provides benefits beyond taking either one alone. Since both converge on the same pathway (both ultimately become NAD+), the theoretical case for combining them is not strong — though the definitive data does not yet exist.

Is plain niacinamide (vitamin B3) just as good as NMN or NR?

This is Brad Stanfield’s argument, and it has some supporting evidence. Niacinamide (nicotinamide) is a form of vitamin B3 that participates in NAD+ synthesis via the salvage pathway. Research has shown it can support NAD+ levels, and it costs a fraction of what NMN or NR costs ($5-10/month vs. $50-100/month). The counterargument, primarily from NMN advocates, is that niacinamide may inhibit sirtuin activity at higher doses, potentially offsetting the benefit of NAD+ elevation. This is an area of active research without clear resolution.

What dose of NMN or NR should someone take?

CoreStacks does not recommend specific dosages. What we can report is what experts and clinical trials have used: David Sinclair has publicly stated he takes 1g NMN daily. Andrew Huberman has mentioned 1-2g NMN daily. Clinical trials have typically used 250mg-1,200mg NMN or 300-1,000mg NR. Brad Stanfield, who does not recommend either, has noted that if someone insists on taking an NAD+ precursor, lower doses (250-500mg) may be sufficient based on the dose-response data in published trials. Any dosing decision should be made with a healthcare provider.

How long does it take for NMN or NR to work?

Published clinical trials show that NAD+ blood levels begin to rise within days of starting supplementation, with peak elevation typically observed within one to two weeks. However, “working” in the sense of producing noticeable health improvements is a different question. Most trials run 8-12 weeks and show variable functional outcomes. The experts who take these supplements typically report evaluating effects over months, not days, using blood work and biomarker tracking. There is no established timeline for when a person should expect to notice subjective benefits, if any.

Are there side effects of NMN or NR?

Published safety data for both NMN and NR has been generally reassuring at standard doses. In clinical trials, commonly reported side effects include mild gastrointestinal discomfort (nausea, bloating) at higher doses. Serious adverse events have not been reported in published human studies at doses up to 1,200mg NMN or 2,000mg NR per day over 8-12 weeks. However, long-term safety data beyond 12 weeks is limited. Peter Attia has raised the theoretical concern that chronically elevating NAD+ could have unintended effects (for example, fueling pre-existing cancer cells), though this has not been demonstrated in human studies. As with any supplement, individual reactions vary, and a healthcare provider should be consulted.

Where can I buy NMN now that the FDA has restricted it?

NMN products continue to be available in the United States through several channels, despite the FDA’s regulatory determination. Brands such as ProHealth Longevity Check current pricing on Amazon, DoNotAge Check current pricing on Amazon, and Renue By Science Check current pricing on Amazon continue to sell NMN products. The legal basis for continued sales varies by company. When purchasing NMN, prioritize brands that provide current Certificates of Analysis from independent third-party labs, as quality control in the NMN market is inconsistent. NR (as Tru Niagen) is available through standard retail channels including Amazon and the ChromaDex website Check current pricing on Amazon.

Keep Reading

Sources

Expert Sources

  • Sinclair, D. Diamandis, P. (June 2025). Interview on longevity protocols and aging research.
  • Sinclair, D. Lifespan: Why We Age — and Why We Don’t Have To. Atria Books, 2019.
  • Huberman, A. Huberman Lab Podcast. Multiple episodes on supplement stacks and NAD+ biology. Stanford University.
  • Huberman, A. Tim Ferriss Show #660. Supplement stack discussion.
  • Attia, P. The Drive Podcast. Multiple episodes on NAD+ precursors, supplement evidence frameworks, and longevity pharmacology.
  • Attia, P. Outlive: The Science and Art of Longevity. Harmony Books, 2023.
  • Stanfield, B. YouTube channel (275K+ subscribers). Multiple videos analyzing NMN, NR, and niacinamide evidence. drstanfield.com.
  • Patrick, R. FoundMyFitness podcast and research summaries on NAD+ biology. foundmyfitness.com.
  • Johnson, B. Blueprint protocol documentation. blueprint.bryanjohnson.com.

Published Research

  • Yoshino, M. et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science 372, 1224-1229 (2021).
  • Yi, L. et al. “The efficacy and safety of NMN supplementation in healthy middle-aged adults.” NEJM correspondence (2023).
  • Igarashi, M. et al. “Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men.” NPJ Aging 8, 5 (2022).
  • Katayoshi, T. et al. NMN supplementation and sleep quality in older adults (2023).
  • Martens, C.R. et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications 9, 1286 (2018).
  • Elhassan, Y.S. et al. “Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures.” Cell Reports 28, 1717-1728.e6 (2019).
  • Dollerup, O.L. et al. “A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men.” Journal of Clinical Endocrinology & Metabolism 103, 3098-3107 (2018).
  • Dollerup, O.L. et al. “Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.” Journal of Physiology 598, 731-754 (2020).
  • Conze, D. et al. “Safety and metabolism of long-term administration of NIAGEN in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults.” Scientific Reports 9, 9772 (2019).
  • Grozio, A. et al. “Slc12a8 is a nicotinamide mononucleotide transporter.” Nature Metabolism 1, 47-57 (2019).
  • Das, A. et al. “Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging.” Cell 173, 74-89.e20 (2018).
  • Mills, K.F. et al. “Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice.” Cell Metabolism 24, 795-806 (2016).

Regulatory Sources

  • FDA. Determination regarding NMN and the dietary supplement definition. (2022-2023).
  • ChromaDex. Niagen GRAS notification and safety data. FDA GRAS Notice GRN 635.

JSON-LD Schema (for implementation)

“`json

{

“@context”: “https://schema.org”,

“@type”: “Article”,

“headline”: “NMN vs NR: What Longevity Experts Actually Recommend in 2026”,

“description”: “A comprehensive comparison of NMN and NR (nicotinamide riboside) for NAD+ supplementation, featuring positions from David Sinclair, Andrew Huberman, Peter Attia, Brad Stanfield, and Rhonda Patrick, plus published clinical trial analysis.”,

“datePublished”: “2026-02-27”,

“dateModified”: “2026-02-27”,

“author”: {

“@type”: “Person”,

“name”: “Mike Hartnett”,

“url”: “https://corestacks.com/author/mike-hartnett/”

},

“publisher”: {

“@type”: “Organization”,

“name”: “CoreStacks”,

“url”: “https://corestacks.com”,

“logo”: {

“@type”: “ImageObject”,

“url”: “https://corestacks.com/logo.png”

}

},

“mainEntityOfPage”: {

“@type”: “WebPage”,

“@id”: “https://corestacks.com/nmn-vs-nr-experts-recommend/”

},

“keywords”: [“NMN”, “NR”, “nicotinamide mononucleotide”, “nicotinamide riboside”, “NAD+”, “longevity supplements”, “David Sinclair”, “Andrew Huberman”, “Peter Attia”, “Brad Stanfield”],

“articleSection”: “Longevity Supplements”

}

“`

“`json

{

“@context”: “https://schema.org”,

“@type”: “FAQPage”,

“mainEntity”: [

{

“@type”: “Question”,

“name”: “Is NMN or NR better for raising NAD+ levels?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “Both NMN and NR have been shown in published human trials to raise blood NAD+ levels significantly. Head-to-head comparison data in humans is limited. David Sinclair argues NMN has a theoretical advantage due to single-step conversion. ChromaDex-funded research shows NR reliably raises NAD+ by 40-90%. The definitive answer remains under investigation.”

}

},

{

“@type”: “Question”,

“name”: “Why did the FDA exclude NMN from being sold as a supplement?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “The FDA determined in 2022-2023 that NMN was being investigated as a new drug before it was marketed as a dietary supplement, which under the Federal Food, Drug, and Cosmetic Act excludes it from the supplement definition. This is a legal determination, not a safety finding. The decision has been challenged by industry groups.”

}

},

{

“@type”: “Question”,

“name”: “Can I take both NMN and NR at the same time?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “Some people do, including Bryan Johnson whose Blueprint protocol includes both. There is no published evidence suggesting combining them is harmful, but also no evidence that combining provides benefits beyond taking either alone, since both converge on the same NAD+ pathway.”

}

},

{

“@type”: “Question”,

“name”: “Is plain niacinamide just as good as NMN or NR?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “Dr. Brad Stanfield argues that low-dose niacinamide (250-500mg/day) can support NAD+ levels at a fraction of the cost. The counterargument is that niacinamide may inhibit sirtuin activity at higher doses. This is an area of active research without clear resolution.”

}

},

{

“@type”: “Question”,

“name”: “What dose of NMN or NR should someone take?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “David Sinclair publicly takes 1g NMN daily. Andrew Huberman mentions 1-2g NMN daily. Clinical trials have used 250mg-1,200mg NMN or 300-1,000mg NR. Any dosing decision should be made with a healthcare provider.”

}

},

{

“@type”: “Question”,

“name”: “Are there side effects of NMN or NR?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “Published safety data for both has been generally reassuring at standard doses. Commonly reported side effects include mild gastrointestinal discomfort at higher doses. Serious adverse events have not been reported in published studies at doses up to 1,200mg NMN or 2,000mg NR over 8-12 weeks. Long-term data beyond 12 weeks is limited.”

}

},

{

“@type”: “Question”,

“name”: “How long does it take for NMN or NR to work?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “NAD+ blood levels begin to rise within days, with peak elevation typically within one to two weeks. However, noticeable health improvements are variable. Most clinical trials run 8-12 weeks with mixed functional outcomes.”

}

},

{

“@type”: “Question”,

“name”: “Where can I buy NMN despite the FDA restriction?”,

“acceptedAnswer”: {

“@type”: “Answer”,

“text”: “NMN products continue to be available from brands like ProHealth Longevity, DoNotAge, and Renue By Science. The legal basis for sales varies. Prioritize brands providing current third-party Certificates of Analysis. NR (as Tru Niagen) is available through standard retail channels.”

}

}

]

}

“`

If you made it this far, you'll like the newsletter. One email per week — the research that matters, the supplements that work, the ones that don't. Free.

Join the Newsletter →

Share Article

Author

Mike Hartnett

Mike tracks what leading longevity researchers actually take, test, and recommend. CoreStacks reports on expert protocols and published research to help you make informed decisions about your health.

Follow Me
Other Articles

Related Posts

Scroll

Our site uses cookies. By using this site, you agree to the Privacy Policy

Accept